Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular disease, including arterial calcification. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in elevations in serum calcium and phosphorus, increasing the risk of vascular calcification in dialysis patients. New vitamin D receptor activators (VDRAs) have been developed and investigated with the rationale to treat high serum PTH levels, with a reduced risk of hypercalcemia and hyperphosphatemia. Paricalcitol is a selective VDRA that suppresses PTH secretion with minimal increases on serum calcium and phosphate. Moreover, paricalcitol prevents vascular calcification in experimental models of renal failure, compared with calcitriol.

The effect of paricalcitol on vascular calcification and cardiovascular disease in uremia : beyond PTH control / M.G. Cozzolino, F. Mehmeti, P. Ciceri, E.M. Volpi, A. Stucchi, I. Brenna, D.M. Cusi. - In: INTERNATIONAL JOURNAL OF NEPHROLOGY. - ISSN 2090-214X. - 2011:(2011), pp. 269060.1-269060.5. [10.4061/2011/269060]

The effect of paricalcitol on vascular calcification and cardiovascular disease in uremia : beyond PTH control

M.G. Cozzolino
Primo
;
F. Mehmeti
Secondo
;
P. Ciceri;E.M. Volpi;A. Stucchi;I. Brenna
Penultimo
;
D.M. Cusi
Ultimo
2011

Abstract

Secondary hyperparathyroidism is a systemic disorder that associates with bone and cardiovascular disease, including arterial calcification. Treatment with calcitriol, the active form of vitamin D, reduces parathyroid hormone levels, but may result in elevations in serum calcium and phosphorus, increasing the risk of vascular calcification in dialysis patients. New vitamin D receptor activators (VDRAs) have been developed and investigated with the rationale to treat high serum PTH levels, with a reduced risk of hypercalcemia and hyperphosphatemia. Paricalcitol is a selective VDRA that suppresses PTH secretion with minimal increases on serum calcium and phosphate. Moreover, paricalcitol prevents vascular calcification in experimental models of renal failure, compared with calcitriol.
Settore MED/14 - Nefrologia
2011
Article (author)
File in questo prodotto:
File Dimensione Formato  
269060.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 490.08 kB
Formato Adobe.pdf
490.08 kB Adobe.pdf Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/159913
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact